EP0413622A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Albumin derivatives with therapeutic functions
Assignee: Aventis Pharma SA
•
Filing: 1990-08-02
•
Granted: —
•
Expires: 2010-08-02
Abstract
Abstract Utilization of albumin as a stable plasma transporter with a therapeutic function that is derived from a membrane receptor. The present invention is exemplified by the description of new therapeutic agents that can be used in the treatment of Acquired Immunodeficiency Syndrome: hybrid macromolecules composed of albumin derivatives coupled to derivatives of the CD4 receptor having a normal or a higher affinity for the HIV-1 virus.
Inventors
- 👤 Jérome Becquart
- 👤 Reinhard Fleer
- 👤 Philippe Hervé Hirel
- 👤 David Robert Klatzmann
- 👤 Didier Landais
- 👤 Jean-François Mayaux
- 👤 Patrice Yeh
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 07:34
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/76; C07K14/765; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/38; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; A61P35/00; C07K14/46; C07K14/47; C07K14/4701; C07K14/4716; C07K14/705; C07K14/70503; C07K14/70514; C07K14/82; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/62; C12N15/63; C12N15/67; C12N15/79; C12N15/80; C12N15/81; C12N15/815; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/31; C07K2319/32; C07K2319/70; C07K2319/73
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
57 words
1/ Hybrid macromolecule characterized by the fact that it carries either the active domain of a receptor for a given virus, or the active domain of a molecule which can bind to the virus, or the active domain of a receptor of a ligand intervening in a pathological process, coupled to albumin or a variant of albumin.
Claim 2
Dependent Claim
57 words
1/ Hybrid macromolecule characterized by the fact that it carries either the active domain of a receptor for a given virus, or the active domain of a molecule which can bind to the virus, or the active domain of a receptor of a ligand intervening in a pathological process, coupled to albumin or a variant of albumin.
Claim 3
Dependent Claim
14 words
2/ Macromolecule according to claim 1, in which the receptor is a membrane receptor.
Claim 4
Dependent Claim
19 words
3/ Macromolecule according to claims 1 and 2, characterized by the fact that such a macromolecule is substantially proteinic.
Claim 5
Dependent Claim
15 words
4/ Macromolecule according to claims 1, 2 or 3, in which the coupling is covalent.
Claim 6
Dependent Claim
17 words
5/ Macromolecule according to claim 4, in which the covalent coupling is accomplished by a peptide linkage.
Claim 7
Dependent Claim
38 words
6/ Macromolecule according to claims 1, 2, 3, 4 or 5, in which the active domain of the receptor is the active domain of a receptor normally used by a virus for its propagation in the host organism.
Claim 8
Dependent Claim
36 words
7/ Macromolecule according to claims 1, 2, 3, 4 or 5, in which the active domain of the receptor is the active domain of a receptor intervening in the internalization of infectious virions complexed to immunoglobulins.
Claim 9
Dependent Claim
25 words
8/ Macromolecule according to claim 7, in which the active domain of the receptor is the active domain of a receptor of the type FcγRIII.
Claim 10
Dependent Claim
22 words
9/ Macromolecule according to claim 8, in which the active domain of the receptor is the active domain of the receptor CD16.
Claim 11
Dependent Claim
32 words
10/ Macromolecule according to claim 1, 2,3,4 or 5 in which the active domain of the receptor is the active domain of a receptor of a factor intervening in an oncogenic process.
Claim 12
Dependent Claim
23 words
11/ Macromolecule according to claim 10, in which the active domain of the receptor is the active domain of a tyrosine kinase-type receptor.
Claim 13
Dependent Claim
24 words
12/ Macromolecule according to claim 11, in which the active domain of the receptor is the active domain of the proto-oncogene c- erbB -2.
Claim 14
Dependent Claim
23 words
13/ Macromolecule according to one of the claims 1 through 12, characterized by the fact that the albumin used is of human origin.
Claim 15
Dependent Claim
58 words
14/ Macromolecule according to one of the claims 1 through 6, in which the receptor is all or part of the CD4 molecule used by the HIV-1 virus for its propagation in the host organism, including all artificial variations of the region of interaction with the virus which have a higher than normal molecular affinity for the virus.
Claim 16
Dependent Claim
23 words
15/ Macromolecule according to claim 14 in which the receptor is made up of the V1 and V2 domains of the CD4 molecule.
Claim 17
Dependent Claim
35 words
16/ Macromolecule according to one of the claims 1 through 15, characterized by the fact that it carries more than one active domain of the receptor or of the molecule capable of binding the ligand.
Claim 18
Dependent Claim
25 words
17/ Macromolecule according to one of the claims 1 through 16, in which albumin or the variant of albumin is localized at the N-terminal end.
Claim 19
Dependent Claim
45 words
18/ Macromolecule according to claim 17 in which a dimerization or polymerization function is incorporated to permit an increase in the local concentration of the active domain of the receptor of the virus or of the receptor of the ligand associated with an oncogenic process.
Claim 20
Dependent Claim
41 words
19/ Macromolecule according to claims 1 to 18 characterized in that it is devoid of proteolytic cleavage sites between the active domain of the receptor or of the molecule capable of binding said ligands, and albumin or said variant of albumin.
Claim 21
Dependent Claim
35 words
20/ Macromolecule according to one of the claims 1 through 19, characterized by the fact that it is obtained by cultivating cells that have been transformed, transfected, or infected by a vector expressing such macromolecule.
Claim 22
Dependent Claim
14 words
21/ Macromolecule according to claim 20, in which the transformed cell is a yeast.
Claim 23
Dependent Claim
18 words
22/ Macromolecule according to claim 21, in which the yeast is a strain of the genus Kluyveromyces .
Claim 24
Dependent Claim
39 words
23/ Macromolecule according to claim 21, in which the vector is an expression vector derived from plasmid pKD1 in which the genes A , B and C , the origin of replication, and the inverse repeats have been conserved.
Claim 25
Dependent Claim
17 words
24/ A macromolecule according to one of the claims 1 through 23, for use as a pharmaceutical.
Claim 26
Dependent Claim
28 words
25/ For use as a pharmaceutical according to claim 24, a macromolecule composed of human albumin or an albumin variant, and the V1 domain of the CD4 molecule.
Claim 27
Dependent Claim
26 words
26/ For use as a pharmaceutical according to claim 25, a macromolecule composed of human albumin or an albumin variant, and the V1V2 domains of CD4.
Claim 28
Dependent Claim
24 words
27/ Cells that have been transformed, transfected, or infected by a vector expressing a macromolecule according to one of the claims 1 through 19.
Claim 29
Dependent Claim
15 words
28/ Cells according the claim 27, characterized by the fact that these cells are yeasts.
Claim 30
Dependent Claim
19 words
29/ Cells according to claim 28, characterized by the fact that the yeast is of the genus Kluyveromyces .
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.